thymalfasin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Impact factor data ... have a strong influence on the scientific community, affecting decisions on where to publish, whom to promote or hire, the success of grant applications, and even salary bonuses. More targeted research has begun to provide firm evidence of how deeply the impact factor is embedded within formal and informal research assessment processes. A review in 2019 studied how often the JIF featured in documents related to the review, promotion, and tenure of scientists in US and Canadian universities. It concluded that 40% of universities focused on academic research specifically mentioned the JIF as part of such review, promotion, and tenure processes. A 2017 study of how researchers in the life sciences behave concluded that "everyday decision-making practices as highly governed by pressures to publish in high-impact journals." It has been argued that the deeply embedded nature of such indicators not only affects research assessment, but the more fundamental issue of what research is actually undertaken: "Given the current ways of evaluation and valuing research, risky, lengthy, and unorthodox project rarely take center stage."
There is high interindividual variability in the levels of estradiol achieved with oral estradiol, which is likely related to the high first-pass effect. This variation has been reported to be in the range of 28 to 127%, or about 4.6-fold maximal difference in levels between individuals, in terms of mean area-under-the-curve levels of estradiol. In postmenopausal women, a dosage of 1 mg/day oral micronized estradiol has been found to produce circulating concentrations of 30 to 50 pg/mL estradiol and 150 to 300 pg/mL estrone, while a dosage of 2 mg/day has been found to result in circulating levels of 50 to 180 pg/mL estradiol and 300 to 850 pg/mL estrone. A study of oral micronized estradiol in transgender women found that mean estradiol levels across a dosage range of 1 to 8 mg/day were about 50 pg/mL at 1 mg/day, 100 pg/mL at 4 mg/day, and 150 pg/mL at 8 mg/day, with a wide degree of variation. In another study, mean estradiol levels at steady state with 4 mg/day and 6 mg/day oral micronized estradiol were approximately 180 pg/mL and 265 pg/mL, respectively. A study that used high to very high-dose oral micronized estradiol in postmenopausal women found that steady-state estradiol levels with 6 mg/day were about 300 pg/mL and with 30 mg/day were about 2,400 pg/mL. Estradiol valerate is rapidly hydrolyzed into estradiol in the intestines. For this reason, oral estradiol and oral estradiol valerate have very similar pharmacokinetics.
As for the Basque Country, Rodríguez Zapatero announced shortly after having rejected on February 1, 2005, in the Congress of Deputies – with the support of the PP – the "Ibarretxe Plan", that he was willing to "dialogue" with ETA to put an end to terrorism. Almost a year later, on March 22, 2006, ETA announced a "permanent ceasefire" and that it would talk with the government about the "end of violence" if in parallel a "table of parties" was formed that would include the outlawed Batasuna. The PP's response was to accuse the government of having unilaterally broken the Antiterrorist Pact of 2000 and then subjected it to intense harassment both in the Cortes and in the streets, supporting the long series of demonstrations against the "surrender" to ETA called by the Association of Victims of Terrorism.
== Medicine == White coats are sometimes seen as the distinctive dress of both physicians and surgeons, who have worn them for over 100 years. In the nineteenth century, respect for the certainty of science was in stark contrast to the quackery and mysticism of nineteenth-century medicine. To emphasize the transition to the more scientific approach of modern medicine, physicians began to represent themselves as scientists, donning the most recognizable symbol of the scientist, the white laboratory coat. The modern white coat was introduced to medicine in the late 1800s as a symbol of cleanliness.
Sources: en.wikipedia.org
=== Modelling metabolism === There are several ways metabolism can be modeled. For some models, a linear excretion rate is preferred. This can be accomplished with a simple differential equation. Otherwise a Michaelis-Menten equation, as follows, is generally appropriate for a more accurate result.
Parkia biglobosa, the African locust bean, is a perennial deciduous tree in the family Fabaceae. It is found in a wide range of environments in Africa and is primarily grown for its pods that contain both a sweet pulp and valuable seeds. Where the tree is grown, the crushing and fermenting of these seeds constitutes an important economic activity. Various parts of the locust bean tree are used for medicinal and food purposes. As a standing tree, locust bean may have a positive effect on the yield of nearby crops, like other leguminous plants.
Williams cites the Mahatanhasankhaya Sutta as showing how dependent origination is to be seen as an alternative theory to such views. According to Williams, dependent origination allows the Buddha to replace a view of the world based on unchanging selves "with an appeal to what he sees as being its essentially dynamic nature, a dynamism of experiences based on the centrality of causal conditioning." Bhikkhu Analayo writes that "dependent arising is the other side of the coin of emptiness, in the sense of the absence of a substantial and unchanging entity anywhere in subjective experience. Experience or existence is nothing but conditions. This leaves no room for positing a self of any type." According to Eisel Mazard, the twelve Nidanas are a description of "a sequence of stages prior to birth", as an "orthodox defense against any doctrine of a 'supernal self' or soul of any kind [...] excluding an un-mentioned life-force (jīva) that followers could presume to be additional to the birth of the body, the arising of consciousness, and the other aspects mentioned in the 12-links formula." According to Mazard, "many later sources have digressed from the basic theme and subject-matter of the original text, knowingly or unknowingly."
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.